No Data
Solasia Pharma Slashes Earnings Forecast for 2024 Due to Sluggish Shipments, Delayed Out-licensing
Emerging Markets stocks digest: DWTI surged, Headwater briefly hit the daily limit up.
＜4576＞ DWTI 201 +38 surged sharply. It announced that it received notification from Kowa, the licensee, that the glaucoma and ocular hypertension treatment "Graa Alpha Combination Eye Drops (domestic product name)" has been approved in Thailand for the Rho kinase inhibitor Ripasudil hydrochloride hydrate it developed, which is viewed favorably. The product has been on the domestic market since December 2022 through Kowa, and discussions were held regarding overseas sales. This is the first time the product has obtained approval overseas, and Kowa will continue to.
Hot Stocks Digest (Morning Session): WNI Weather, Marumae, Headwater, ETC.
Sumitomo Electric Industries <5802>: 2845 yen (-39.5 yen) fell back. It has been reported that they will abandon plans for mass production of semiconductor materials for electric vehicles. In addition to constructing a new factory in Toyama Prefecture, there were plans to establish a new line at an existing factory in Hyogo Prefecture, but it seems that these plans are being retracted due to the uncertain recovery of EV demand. The total investment amount was expected to be 30 billion yen. They were set to receive up to 10 billion yen in subsidies from the Ministry of Economy, Trade and Industry for the factory construction, but this has also been canceled. This is due to a change in the long-term Global Strategy.
Solexia - Significant decline, discontent with the downward revision of the full-year Financial Estimates for the fiscal year ending December 2024.
A significant drop. After the close of trading on the 27th, it was announced that the financial estimates for the fiscal year ending December 2024 were revised downward, leading to an initial sell-off. Revenue is revised down by 1.09 billion yen from the previous estimated value (lower limit) to 0.16 billion yen. The sales partner had anticipated completing the shipment of inventory around mid-year, but in reality, shipments Stunk, resulting in low shipment volume of new facility manufactured products this year. Additionally, the anticipated rights derivation of Darubias in China that was part of the previous financial estimates has not materialized.
Weakness, weighed down by factors such as falling US stocks [emerging markets individual stock strategy]
[Emerging Markets Individual Stock Strategy] Today's Emerging Markets are expected to experience a weak performance. In the U.S. stock market on the weekend of the 27th, the Dow Inc fell by 333.59 points (-0.77%) to 42,992.21 dollars, marking a downturn after six days. With limited participants as the year-end approaches, profit-taking selling occurred. In particular, technology stocks were sold off in anticipation of rebalancing for the new fiscal year, dragging down the overall market. The Emerging Markets today are likely to see a dominant selling trend. Given that major indices fell in the U.S. stock market last weekend and that Overseas market.
DWTI, Architects SJ and others.
＜1447＞ Acquisition and cancellation of all remaining subscription rights of the 4th series (with exercise price adjustment clause) of SAAFD. ＜3557＞ Large exercise of the 9th subscription rights (with exercise price adjustment clause) of U&C from the 4th, number of shares delivered, 0.07 million, 2000 shares. ＜4576＞ Approval obtained in Thailand for the glaucoma and ocular hypertension treatment "Grau Alpha combination eye drops (domestic product name)" of DWTI. ＜4586＞ Termination of joint research contract with Medrec Fanpepp. ＜4881＞ Soleasia's downward revision, current period operations.
No Data